Top

Published in:

01-02-2021 | Esophageal Cancer | Thoracic Oncology

Don’t Anger the Host: New Etiquette in Standard Cancer Assessment?

Authors: Kei Suzuki, MD, Virginia R. Litle, MD

Published in: Annals of Surgical Oncology | Issue 2/2021

Excerpt

Immune responses within the tumor microenvironment are increasingly implicated as markers of malignant progression and aggression. Interactions between tumor, immune cells, and cytokines can shift the tumor’s microenvironment to welcoming or hostile.1 This host–tumor interaction may be reflected in the peripheral blood, and investigation of the host inflammatory response in the peripheral blood of cancer patients may potentially provide a simple tool for clinical decision-making. …

Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res. 2011;17(16):5247–56.PubMedCrossRef

McSorley ST, Lau HYN, McIntosh D, et al. Staging the tumor and staging the host: Pretreatment combined neutrophil lymphocyte ratio and modified Glasgow Prognostic Score is associated with overall survival in patients with esophagogastric cancers undergoing treatment with curative intent. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09074-5.

Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–39.PubMedCrossRef

Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014;232(2):199–209.PubMedCrossRef

Sulibhavi A, Asokan S, Miller MI, et al. Peripheral blood lymphocytes and platelets are prognostic in surgical pT1 non-small cell lung cancer. Ann Thorac Surg. 2020;109(2):337–42.PubMedCrossRef

Pirozzolo G, Gisbertz SS, Castoro C, van Berge Henegouwen MI, Scarpa M. Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis. J Thorac Dis. 2019;11(7):3136–45.PubMedPubMedCentralCrossRef

Zhang J, Zhang H-Y, Li J, Shao X-Y, Zhang C-X. The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(40):68837–46.PubMedPubMedCentralCrossRef

Jin H, Sun J, Zhu K, et al. The prognostic value of neutrophil-lymphocyte ratio is superior to derived neutrophil-lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up. OncoTargets Therapy. 2017;10:2655–64.PubMedCrossRef

Zhou XL, Li YQ, Zhu WG, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Sci Rep. 2017;7:42581.PubMedPubMedCentralCrossRef

10.

Barbetta A, Nobel TB, Sihag S, et al. Neutrophil to Lymphocyte ratio as predictor of treatment response in esophageal squamous cell cancer. Ann Thorac Surg. 2018;106(3):864–71.PubMedPubMedCentralCrossRef

11.

Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: A systematic review and meta-analysis. Ann Surg Oncol. 2016;23(2):646–54.PubMedCrossRef

12.

McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.PubMed

13.

Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis. Sci Rep. 2017;7(1):16717.PubMedPubMedCentralCrossRef

14.

Egyud M, Tejani M, Pennathur A, et al. Detection of circulating tumor DNA in plasma: a potential biomarker for esophageal adenocarcinoma. Ann Thorac Surg. 2019;108(2):343–9.PubMedPubMedCentralCrossRef

Title: Don’t Anger the Host: New Etiquette in Standard Cancer Assessment?
Authors: Kei Suzuki, MD
Virginia R. Litle, MD
Publication date: 01-02-2021
Publisher: Springer International Publishing
Keywords: Esophageal Cancer
Esophageal Cancer
Published in: Annals of Surgical Oncology / Issue 2/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-09285-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Don’t Anger the Host: New Etiquette in Standard Cancer Assessment?

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2021

Robotic Gastrectomy for Gastric Adenocarcinoma in the USA: Insights and Oncologic Outcomes in 220 Patients

Total Parietal Peritonectomy Can Be Performed with Acceptable Morbidity for Patients with Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: Results From a Prospective Multi-centric Study

Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy

Distal Gastrectomy with Billroth II Reconstruction is Associated with Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study

Prognostic Factors for Surgically Resected Intraductal Papillary Neoplasm of the Bile Duct: A Retrospective Cohort Study

First Case of Full Robotic ALPPS for Intrahepatic Cholangiocarcinoma